ReviewPancreas2018
Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.
Review in Pancreas, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Improving predictive accuracy for surgical indication of the current management guideline for intraductal papillary mucinous neoplasm of the pancreas via cutoff adjustments.European radiology · 2026Article
- Article
- Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas: current understanding and perspectives on malignant progression.Journal of gastroenterology · 2026Review
- Evaluation of cystic neoplasms using EUS, MRI, and CT scan and treatment strategy.Annals of medicine and surgery (2012) · 2026Review
- Cystic neoplasms of pancreas.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Punctate Palmoplantar Keratoderma Type 1 (PPPK1) Associated with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN): A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Review
- Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- GATA6 in pancreatic cancer initiation and progression.Genes & diseases · 2025Review
- An imaging-based model to predict the malignant potential of intraductal papillary mucinous neoplasm of the pancreas.European radiology · 2025Article
- Diagnostic and therapeutic guidelines for pancreatic cystic tumors: recommendations of Polish Pancreatic Club experts.Przeglad gastroenterologiczny · 2025Article
- Gastrointestinal Cancer Precursor Conditions and Their Detection.Hematology/oncology clinics of North America · 2024Review
- Benign Etiology for High-Risk Intraductal Papillary Mucinous Neoplasm: A Case Report and Literature Review.Cureus · 2024Article
- Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.Journal of surgical oncology · 2023Observational
- SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.Scientific reports · 2023Article
- The Use of Integrated Molecular Testing in the Assessment and Management of Pancreatic Cysts.Current gastroenterology reports · 2023Review
- Synchronous manifestation of colorectal cancer and intraductal papillary mucinous neoplasms.World journal of clinical cases · 2023Review
- Diagnostic, Structured Classification and Therapeutic Approach in Cystic Pancreatic Lesions: Systematic Findings with Regard to the European Guidelines.Diagnostics (Basel, Switzerland) · 2023Review
- Pancreatic Intraductal Papillary Mucinous Neoplasms: A Narrative Review.Acta medica Lituanic · 2023Review
- Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak.Surgery · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of intraductal papillary mucinous neoplasms (IPMNs) has been increasing over the past decade, mainly owing to increased awareness and the increased use of cross-sectional imaging. The Sendai and Fukuoka consensus guidelines provide us with clinical management guidelines and algorithms; however, the clinical management of IPMNs continues to be challenging. Our incomplete understanding of the natural history of the disease, and the events and pathways that permit progression to adenocarcinoma, result in difficulties predicting which tumors are high risk and will progress to invasive disease. In this review, we summarize the current management guidelines and describe ongoing efforts to more clearly stratify IPMNs by risk of malignancy and identify IPMNs with malignant potential or ongoing malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.